Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Analgesic

or Atypical antipsychotic

or Neuroleptic

Use the filters below to narrow your results.

None (3) · Asenapine (1) · Buprenorphine (1) · Butorphanol (1) · Chlorpromazine (1) · Clozapine (1) · Codeine (2) · Dextropropoxyphene (1) · Dihydrocodeine (1) · Droperidol (1) · Ethylmorphine (1) · Fentanyl (1) · Fluphenazine (1) · Hydrocodone (1) · Hydromorphone (1) · Iloperidone (1) · Levorphanol (1) · Loxapine (1) · Lurasidone (1) · Meperidine (1) · Methadone (1) · Molindone (1) · Nalbuphine (1) · Oxymorphone (1) · Paliperidone (1) · Papaverine (1) · Pentazocine (1) · Perphenazine (1) · Pimozide (1) · Tapentadol (1) · Thioridazine (1) · Thiothixene (1) · Trifluoperazine (1) · Ziprasidone (1)

None (5) · (multiple, generic dominant) (1) · Caplyta (1) · Clozaril (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Dolophine (1) · Duragesic (1) · Fanapt (1) · Geodon (1) · Inapsine (1) · Invega (1) · Latuda (1) · Loxitane (1) · Mellaril (1) · Moban (1) · Navane (1) · Nubain (1) · Nucynta (1) · Opana (1) · Orap (1) · Prolixin (1) · Rexulti (1) · Saphris (1) · Stadol (1) · Stelazine (1) · Suboxone (1) · Talwin (1) · Thorazine (1) · Trilafon (1) · Vicodin (1) · Vraylar (1)

None (2) · Butyrophenone D2 antagonist (1) · D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) · D2/5-HT2A antagonist (1) · D2/5-HT2A antagonist; 5-HT7 antagonist (1) · D2/5-HT2A antagonist; active metabolite of risperidone (1) · D2/5-HT2A antagonist; SRI and NRI (1) · Dibenzoxazepine D2/5-HT2 antagonist (1) · Dihydroindolone D2 antagonist (1) · Diphenylbutylpiperidine D2 antagonist (1) · Kappa agonist; mu antagonist (1) · Kappa agonist; mu partial agonist (1) · Kappa agonist; mu partial agonist/antagonist (1) · Mu-opioid agonist; norepinephrine reuptake inhibitor (1) · Mu-opioid receptor agonist (4) · Mu-opioid receptor agonist; NMDA antagonist (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Mu-opioid receptor agonist; sodium channel blocker (1) · Mu/kappa/delta agonist; NMDA antagonist (1) · Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) · Multi-receptor antagonist; low D2 affinity (1) · Partial agonist at D2 and 5HT1A. Antagonist at 5HT2A, α1A, α1B, α2C. More potent 5HT2A antagonism, 5HT1A partial agonism, and α1 antagonism (relative to D2 partial agonism) than aripiprazole, proposed to reduce akathisia and enhance affective/cognitive effects. (1) · Partial mu-opioid agonist; kappa antagonist (1) · Phenothiazine D2 antagonist (4) · Phosphodiesterase inhibitor; calcium channel blocker (1) · Potent mu-opioid receptor agonist (3) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · Thioxanthene D2 antagonist (1)

None (33) · Mild to moderate pain; cough suppression (low-dose). (1) · Schizophrenia (FDA-approved 2015). Acute manic or mixed episodes of bipolar I disorder. Bipolar I depression (FDA-approved 2019). Adjunctive treatment of major depressive disorder (FDA-approved Dec 2022). (1) · Schizophrenia (FDA-approved 2015). Adjunctive treatment of major depressive disorder (2015). '''Agitation associated with dementia due to Alzheimer disease''' (FDA-approved May 2023, first agent specifically approved for this problem). Investigational for PTSD (combined with sertraline). (1) · Schizophrenia (FDA-approved Dec 2019). Bipolar depression as monotherapy or adjunct to lithium/valproate (FDA-approved Dec 2021). (1)

None (33) · 42 mg PO once daily with food (no titration) (1) · Adult: 15–60 mg every 4 hours as needed. (1) · Schizophrenia: 1 mg PO daily × 4 days, then 2 mg daily × 3 days, then 4 mg daily. MDD adjunct: 0.5-1 mg daily, increase to 2 mg max. AD agitation: 0.5 mg daily, titrate to 2-3 mg daily. (1) · Schizophrenia: 1.5 mg PO daily, increase to 1.5-6 mg as tolerated. Bipolar mania: 1.5 mg, may increase to 3-6 mg. Bipolar depression: 1.5 mg daily for 14 days, then 3 mg. MDD adjunct: 1.5 mg, may increase to 3 mg. (1)

None (33) · 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg tablets (1) · 1.5 mg, 3 mg, 4.5 mg, 6 mg capsules (1) · 42 mg capsules (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (33) · 360 mg/day (1) · 4 mg/d (schizophrenia); 3 mg/d (AD agitation); 3 mg/d (MDD adjunct) (1) · 42 mg/d (1) · 6 mg/d (psychosis/mania); 3 mg/d (depression adjunct) (1)

None (33) · Oral (3) · PO (only formulation marketed in the US). (1)

None (33) · 30–60 min (PO) (1) · Antipsychotic effect over weeks (1) · Weeks for psychosis/depression; AD agitation benefit emerges over weeks (1) · Weeks for psychosis/mood efficacy (1)

None (33) · 4–6 hours (1) · Daily dosing (2) · Daily dosing; active metabolites with very long half-lives (up to 1-3 weeks) (1)

None (33) · 2.5–3 hours (1) · Cariprazine ~2-4 d; major active metabolites desmethyl-cariprazine (DCAR) ~1-3 weeks → 'oral depot' effect with delayed steady-state and reduced effect of missed doses (1) · ~18 hours (terminal) (1) · ~91 hours (1)

None (33) · Adequate oral bioavailability (1) · Limited but adequate; take with food (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~95% (1)

None (33) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Limited data (1) · Limited data; National Pregnancy Registry available (1) · Limited data; National Pregnancy Registry for Atypical Antipsychotics (1)

None (33) · Rx (3) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1)